These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 12459940

  • 1. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group.
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [Abstract] [Full Text] [Related]

  • 2. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
    Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H.
    J Bone Miner Metab; 2004 Dec; 22(5):469-78. PubMed ID: 15316868
    [Abstract] [Full Text] [Related]

  • 3. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 4. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
    Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R.
    Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
    Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP.
    J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
    [Abstract] [Full Text] [Related]

  • 6. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
    Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M.
    J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212
    [Abstract] [Full Text] [Related]

  • 7. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ, Naganathan V, Barton I, Grauer A.
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [Abstract] [Full Text] [Related]

  • 8. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
    Nakamura T, Maekawa S, Morinobu S, Morinobu A, Koshiba M, Yamauchi M, Sugimoto T, Kumagai S.
    Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
    [Abstract] [Full Text] [Related]

  • 9. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA.
    Arthritis Rheum; 1999 Nov; 42(11):2309-18. PubMed ID: 10555025
    [Abstract] [Full Text] [Related]

  • 10. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES.
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [Abstract] [Full Text] [Related]

  • 11. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators.
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [Abstract] [Full Text] [Related]

  • 12. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
    Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H.
    Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S.
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [Abstract] [Full Text] [Related]

  • 14. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
    Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, Hirakata M, Kuwana M.
    J Rheumatol; 2008 Jan; 35(1):142-6. PubMed ID: 18050368
    [Abstract] [Full Text] [Related]

  • 15. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, Ernst TF, Wenderoth D.
    Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
    [Abstract] [Full Text] [Related]

  • 16. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
    Sebaldt RJ, Ioannidis G, Adachi JD, Bensen WG, Bianchi F, Cividino A, Gordon M, Kaminska E, Scocchia T, Petrie A, Stephenson GF, Goldsmith CH.
    J Rheumatol; 1999 Jul; 26(7):1545-9. PubMed ID: 10405943
    [Abstract] [Full Text] [Related]

  • 17. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K.
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S, Manguso F, Orio F, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P.
    Menopause; 2008 Aug; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [Abstract] [Full Text] [Related]

  • 19. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP.
    Arch Intern Med; 2003 Oct 13; 163(18):2237-46. PubMed ID: 14557222
    [Abstract] [Full Text] [Related]

  • 20. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ.
    N Engl J Med; 1990 Jul 12; 323(2):73-9. PubMed ID: 2113611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.